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ABSTRACT
 
 نيذلا ىضرلما يف نوهدلا ةبسن عافترا ىدم نع ةماع ةلمح يمدقتل  :فادهلأا
 نوهدلا  ضفخب  جلاعلا  مادختسا  ةيفيكو  ،اًدج  ةيلاع  رطاخم  نم  نوناعي
.ةيعقاو ةئيب يف )LLT(
 تايطعلما  عمج  تم  ،زكارلما  ةددعتم  ةظحلالما  ةساردلا  هذه  يف   :ةقيرطلا
 ةكلملما يف رقتسلما ACS وأ CHD ءاودب اولجوع نيذلا LLT ىضرم نم
 18  نم ينغلابلا  دارفلأا جاردإ تم .م2014  و م2013  ينب ةيدوعسلا ةيبرعلا
 بيبطلا  ةرايز  لبق  امإ  لجسم  ،نوهدلل  لماك  فلم  مهيدل  ناكو  اًماع
 ىفشتسلما لوخد نم ةعاس 24 نوضغ يف وأ )CHD ىضرم( يساسلأا
.)ACS ىضرم(
 عم  597  و  ،ةساردلا  يف  اضيرم  737  ىلع  ةساردلا  تلمتشا   :جئاتنلا
 نم  يأ  يف  ىضرلما  نم  ليلق  ددع  .ACS  عم  140  و  رقتسم  CHD
 يذلاو ، رتليسيد / غلم >70 نم LDL-C ىوتسم مهيدل ينتعومجلما
 ىلع  11.4٪ و  24.3٪(  ًادج ةيلاع  رطاخلم  ينضرعلما  ىضرملل  همعد  متي
 )CHD( لد / غم 19.0 ةميقلا هذهل تافاسلما تناكو طسوتلما .)يلاوتلا
 نم  ةضفخنم  تاعرج  مادختسا  تم  .)ACS(  رتليسيد  /  غلم  25.0  و
 ACS و CHD ل موي / غلم 24 و 31( لورتسيلوكلل ةضفخلما ريقاقعلا
 لوخد دعب ACS ىضرلم طقف ىندلأا دلحا فيثكت عم ، )يلاوتلا ىلع ،
.)ةعباتلما يف موي / مجم 41( ىفشتسلما
 ىضرملل  ةئيس  اهب  ىصولما  LDL-C  تايوتسم  قيقتح  ناك   :ةتمالخا
 ةدش تناك .ACS وأ ةرمتسلما ةيجاتلا ينيارشلا ضارمأ نم نوناعي نيذلا
 ىضرلما ءلاؤه جلاع فيثكتل ريبك قاطن ىلإ ريشي امم ، ةضفخنم ينتاتسلا
.رطاخلما ةيلاع
Objectives: To provide an overview of the extent of 
hyperlipidemia in very high-risk patients, and how 
lipid-lowering therapy (LLT) is used in a real-world 
setting. 
Methods: In this multicenter observational study, 
data were collected from LLT-treated patients with 
stable CHD or an ACS in Saudi Arabia between 2013 
and 2014. Individuals were included if they were >18 
years and had a full lipid profile available, recorded 
either prior to the baseline physician visit (CHD 
patients) or within 24-hours of admission to hospital 
(ACS patients). 
Results: A total of 737 patients were included in the 
study, 597 with stable CHD and 140 with ACS. Few 
patients in either group had an LDL-C level of <70 
mg/dl, which is advocated for very high-risk patients 
(24.3% and 11.4%, respectively). The median 
distances to this value were 19.0 mg/dl (CHD) and 
25.0 mg/dl (ACS). Low doses of statins were being 
utilized (31 and 24 mg/day for CHD and ACS, 
respectively), with only minimal intensification for 
the ACS patients after hospital admission (41 mg/day 
at follow-up).
Conclusions: Achievement of recommended LDL-C 
levels was poor for patients with stable CHD or an 
ACS. Statin intensity was low, indicating huge scope 
for intensifying the treatment of these very high-risk 
patients.
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It is well-established that patients with coronary heart disease (CHD) are at very high risk for experiencing 
an adverse cardiovascular event. Such risk can be 
reduced by careful management of associated risk 
factors, including hypertension, diabetes mellitus, and 
dyslipidemia.1,2 Lipid abnormalities, such as high levels 
of low-density lipoprotein cholesterol (LDL-C) or 
triglycerides, and low levels of high-density lipoprotein 
cholesterol (HDL-C), are known to be highly prevalent 
in patients with CHD.3 Indeed, in a recent study of 
CHD patients in Saudi Arabia, 76.7% were found to 
have dyslipidemia.4 The benefits of reducing LDL-C 
levels in particular have been extensively studied in the 
context of decreasing the occurrence of cardiovascular 
events. Indeed, it has been shown that a reduction in 
LDL-C of approximately 39 mg/dl (1 mmol/l) could 
decrease the 5-year rate of major vascular events by 
approximately a fifth.
Evidence-based guidelines for the treatment of 
dyslipidemia from the European Society of Cardiology 
(ESC) and the European Atherosclerosis Society 
(EAS) advocate a target LDL-C level of <70 mg/dl 
(1.81 mmol/l) for patients at very high cardiovascular 
risk, such as those with established CHD.5 Lipid-
lowering therapies (LLTs) such as statins have been 
shown to effectively reduce levels of LDL-C; however, 
despite their widespread use, significant numbers of 
high risk CHD patients fail to achieve target levels. In 
the Middle Eastern cohort of the first Dyslipidemia 
International Study (DYSIS), only 30.5% of the 
statin-treated group at highest cardiovascular risk had 
an LDL-C level below 70 mg/dl.6 Results from the 
Arabian Gulf countries included in the Centralized 
pan-Middle East Survey on the Undertreatment of 
Hypercholesterolemia (CEPHEUS) showed 31.9% 
achievement of the same LDL-C target for the very 
high-risk patients being treated with LLT.7 The 
EUROASPIRE studies have demonstrated increasing 
statin use in patients with CHD over the last decades; 
however, in their most recent analysis, only 19.5% of 
patients had an LDL-C level below 70 mg/dl.8 In a 
single-center study in Saudi Arabia, few CHD patients 
had a recent lipid profile recorded in their medical 
notes, indicating poor monitoring of hyperlipidemia in 
these high-risk patients.9
In order to obtain details on the management of 
cholesterol in patients with CHD, and to evaluate 
current treatment practices, DYSIS II was initiated.10 
This was a multinational, observational study 
investigating lipid abnormalities in patients with either 
stable CHD or presenting with an acute coronary 
syndrome (ACS). With the use of standardized 
methodology, the prevalence of lipid abnormalities, and 
predictors of LDL-C target attainment, was evaluated 
in patients from countries throughout the world. 
Here, we present the results collected in Saudi Arabia, 
providing an overview of the extent of hyperlipidemia 
in these very high-risk patients, and how LLT is used in 
a real-world setting.
Methods. Patients were enrolled at 4 centers within 
Saudi Arabia from December 2013 to October 2014. 
Individuals with either stable CHD or those admitted 
to the hospital with an ACS were included if they 
were over 18 years of age and had a full lipid profile 
available. Acute coronary syndrome was defined as an 
ST-segment elevation myocardial infarction (STEMI)/
left bundle branch block myocardial infarction (LBBB 
MI), non-ST-segment elevation myocardial infarction 
(NSTEMI), or unstable angina (UA) at the time of 
hospital admission. For patients with CHD, the lipid 
profile was obtained from the last blood test within 
the 12 months prior to the baseline physician visit; for 
patients with an ACS, the lipid profile was recorded 
within 24 hours of admission to the hospital. Patients 
were included in the present analysis if they had 
been receiving LLT for at least 3 months prior to the 
latest lipid test. Patients were excluded if they were 
participating in a clinical trial at the same time as the 
study, and for the ACS patients, if they died during the 
hospital stay. For CHD patients, data were collected at 
the baseline physician visit. For ACS patients, data were 
collected on admission to the hospital and at 4 months 
(±15 days) post-admission.
All included patients provided written informed 
consent. The study received ethical approval from 
the relevant national and regional committees at each 
participating center, and was carried out in accordance 
with the Declaration of Helsinki and its amendments.
Disclosure. Gitt has received honoraria from Merck & 
Co., Inc., Kenilworth, NJ, USA for contribution to the 
DYSIS study. M. Horack reports that his institution 
received funding for recruitment and biostatistics for 
the DYSIS registry. A Vyas was a full time employee of 
Rutgers University which received funding from Merck 
& Co., Inc., Kenilworth, NJ USA at the time this 
work was conducted.  (Dr. Vyas is currently employed 
by the University of Rhode Island). Atif Bin Shafi 
Shafiurrehman, S Wajih, B. Ambegaonkar, P. Brudi, D. 
Lautsch, and C. Baxter are employees of Merck & Co., 
Inc., Kenilworth, NJ USA or Merck Sharp & Dohme.
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Data were recorded on a standardized case 
report form (CRF) and later entered into a central 
web-based database maintained at the Institut für 
Herzinfarktforschung, Ludwigshafen, Germany.
Demographic and clinical variables were collected at 
baseline, including age, gender, and body mass index 
(BMI); presence of hypertension or type 2 diabetes 
mellitus; a sedentary lifestyle or smoking; a history of 
CHD, peripheral artery disease (PAD), chronic renal 
failure (CRF), or chronic kidney disease (CKD); a 
prior MI or stroke (ischemic or hemorrhagic); and any 
family history of CHD. Obesity was defined as BMI 
>30 kg/m². Diabetes was defined as current treatment 
for diabetes, a previous diagnosis of diabetes, or a fasting 
plasma glucose level of ≥126 mg/dl. Hypertension was 
defined as current treatment, a previous diagnosis, or 
having blood pressure of >140/90 mm Hg. A sedentary 
lifestyle was defined as <20-30 minutes of walking on 
<3-4 days per week. Use of cardiovascular medications 
(beta-blockers, calcium channel blockers, diuretics, 
ACE inhibitors, antiplatelet agents) and laboratory 
values of HbA1c and blood glucose at admission were 
also documented. A full lipid profile, which included 
measurement of serum levels of total cholesterol (TC), 
LDL-C, HDL-C, non-HDL-C, and triglycerides was 
recorded at baseline. For the ACS patients, any further 
lipid profiles available from the follow-up period were 
also collected.
For ACS patients, pre-ACS cardiovascular risk status 
was determined according to the ESC/EAS guidelines, 
and targets for LDL-C for very high-risk patients 
were defined as <70 mg/dL, high-risk <100 mg/dL, 
moderate-risk <115 mg/dL, and low-risk <130 mg/dL.5 
As shown in the guidelines, very high- and high-risk 
patient groups have clearly set target values based on 
comorbidity, while additional risk factors or markers 
such as obesity or high C-reactive protein (CRP) are 
taken into account for moderate and low cardiovascular 
risk. Low-density lipoprotein cholesterol goal attainment 
was judged based on lipid values at admission, reflecting 
the pre-admission lipid levels. The median distance to 
the LDL-C target was calculated for patients who had 
not attained this level on the date of the lipid profile.
Details of the LLT that each patient was being treated 
were documented. The following classes of LLT were 
assessed: statin monotherapy, non-statin monotherapy, 
statin plus ezetimibe, and statin plus other non-statin 
therapy (other non-statins included nicotinic acids, 
fibrates, omega-3 fatty acids, and other less common 
agents). The statins assessed were atorvastatin, fluvastatin, 
lovastatin, pravastatin, pitavastatin, rosuvastatin, and 
simvastatin. Atorvastatin dose equivalents were based 
on clinical trial data regarding the LDL-C-lowering 
efficacy of various statins. 
For ACS patients, at 4 months (±15 days) post-
admission, any lipid profiles obtained since hospital 
discharge were collected. The median distance to the 
LDL-C target was calculated for patients who had not 
attained the LDL-C target on the date of the lipid profile. 
Any occurrence of cardiovascular-related adverse events 
(rehospitalization, MI, stroke, percutaneous coronary 
intervention [PCI], or coronary artery bypass grafting 
[CABG]) during the follow-up period was recorded. 
These outcomes were not mutually exclusive.
Statistics analysis. Data are presented as means with 
standard deviations (SD), medians with interquartile 
ranges (IQR), or absolute values with percentages. 
Statistical significance was determined using the 
Chi-squared test or the Mann-Whitney-Wilcoxon test. 
Multivariate logistic regression was conducted in 
order to identify any predictors of a patient having 
an LDL-C level below 70 mg/dl. The covariates were 
age, female gender, obesity, current smoking, sedentary 
lifestyle, stable angina, CKD, type 2 diabetes mellitus, 
history of congestive heart failure [CHF], hypertension, 
and statin dose [atorvastatin dose equivalent]). 
Data were analyzed using SAS version 9.3 (Cary, NC, 
USA) and a p-value <0.05 was considered statistically 
significant.
Results. Five hundred and ninety-seven LLT-treated 
patients with stable CHD were recruited (Table 1). The 
mean age of these subjects was 62.5 (±9.8) years and 
79.2% were male. Obesity was recorded for 58.8% of the 
population. Other cardiovascular risk factors included 
current smoking (16.8%), a sedentary lifestyle (69.4%), 
and a family history of CHD (21.6%). Hypertension 
was highly prevalent, being found in 76.5% of patients. 
Greater than 50% stenosis was observed by coronary 
angiography for 45.4% of patients, and by cardiac 
computed tomography for 1.2%. A total of 39.5% of 
patients had previously undergone PCI, 20.9% had 
undergone CABG, and 7.2% had experienced an ACS 
>3 months prior to the physician visit. 
One hundred and forty LLT-treated patients 
admitted to the hospital with an ACS were enrolled 
in the study (Table 1). The mean age of these subjects 
was 62.9 (±8.6) years and 77.1% were male. Obesity 
was recorded for 79.3% of the population. A high 
proportion (75%) reported a sedentary lifestyle, while 
current smoking (41.4%) and a family history of CHD 
(17.3%) were also common. The majority of patients 
had hypertension (74.3%), and many had type 2 
diabetes mellitus (54.3%). The primary ACS diagnosis 
was STEMI for 65% of patients and a NSTEMI for 
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16.4%. The remaining patients (18.6%) were diagnosed 
with UA. 
Lipid profile at time of latest lipid test. For the CHD 
patients, the mean LDL-C level was 84.2 (±23.9) mg/dl, 
with only 24.3% having a value below the ESC/EAS 
target of 70 mg/dl (Table 2).  
Multivariate logistic regression identified type 
2 diabetes mellitus as being predictive of achieving 
an LDL-C level of <70 mg/dl (adjusted odds ratio 
(AOR): 1.81; 95% confidence interval (CI): 1.14-2.89; 
p=0.01), while a sedentary lifestyle (AOR: 0.35; 95% 
CI: 0.30-0.55, p<0.0001) lowered the likelihood of 
target value attainment (Table 3).
For the ACS patients, 11.1% (15/135) of those 
at very high risk and 50% (1/2) of those at high risk, 
but none of those at moderate risk (0/3), according to 
pre-ACS risk level, were at their respective LDL-C target 
at hospital admission. As per the ESC/EAS guidelines, 
all patients were classed as being at very high risk on 
admission, owing to their presentation with an ACS.5 
The mean LDL-C value for the ACS patients, measured 
within 24 hours of admission, was 103 (±42.9) mg/dl 
(Table 2). 
Only 11.4% of this population had an LDL-C level 
of <70 mg/dl. The median distance to this value was 
25.0 (19.0, 50.0) mg/dl. The median HDL-C level was 
35.0 (34.0, 43.0) mg/dl, the median non-HDL-C level 
was 162.0 (130.0, 184.5) mg/dl, the mean TC level was 
198.5 (±61.0) mg/dl, and the median triglyceride level 
was 115.0 (106.0, 124.0) mg/dl. Multivariate logistic 
regression using data collected at hospital admission, 
found that an age equal or greater to 70 years was 
associated with an increased likelihood of having 
an LDL-C level of <70 mg/dl (AOR: 8.16; 95% CI 
1.79-37.30; p=0.0068) (Table 3).
During the 4-month follow-up period, a lipid profile 
was collected for 21 of the patients. Of these, none had 
an LDL-C level of <70 mg/dl at admission and one 
(4.8%) had reached this target by the follow-up point.
Lipid-lowering therapy. Of the stable CHD patients, 
84.3% were on statin monotherapy, while 14.6% were 
on a combination of a statin and ezetimibe, and 1% 
on a combination of a statin and other non-statin 
(Table 4). Atorvastatin was the most commonly 
Table 1 - Characteristics at baseline of 140 lipid-lowering therapies-
treated patients admitted to the hospital with an ACS.
Characteristics Stable CHD
n=597
ACS
n=140
Age (years) 62.5 ± 9.8 62.9 ± 8.6
Male (%) 79.2 (473/597) 77.1 (108/140)
BMI (kg/m2) 30.9 (28.0, 33.4) 33.1 (30.8, 35.3)
BMI >30 kg/m2 (%) 58.8 (351/597) 79.3 (111/140)
SBP (mmHg) 130 (122, 135) 130 (126, 136)
DBP (mmHg) 75 (68, 81) 78 (69, 82)
CV risk factors (%)
Current smoker 16.8 (100/597) 41.4 (58/140)
Sedentary lifestyle 69.4 (414/597) 75.0 (102/136)
Family history of CHD 21.6 (123/569) 17.3 (23/133)
Comorbidities (%)
Type 2 diabetes mellitus 55.8 (333/597) 54.3  (76/140)
Hypertension 76.5 (457/597) 74.3 (104/140)
CKD 7.7 (46/597) 5.0 (7/140)
Prior stroke* 4.3 (25/576) 5.7 (8/140)
History of PAD 3.9 (22/569) 7.9 (11/140)
Data presented as mean ± standard deviation, median (interquartile 
range), or percentage (n/N). *includes ischemic and hemorrhagic stroke. 
CHD - coronary heart disease, ACS - acute coronary syndrome, 
BMI - body mass index, SBP - systolic blood pressure,  DBP - diastolic 
blood pressure, CV - cardiovascular, CKD - chronic kidney disease,  PAD 
- peripheral artery disease. 
Table 2 - Baseline lipid profile of both cohort of ACS and CHD enrolled in hyperlipidemia in Saudi 
Arabia study.
Lipid profile CHD
n=597
ACS
n=140
LDL-C (mg/dl); mean ± SD 84.2 ± 23.9 103.0 ± 42.9
HDL-C (mg/dl); median (IQR) 35.0 (32.0, 42.0) 35.0 (34.0, 43.0)
Non-HDL-C (mg/dl); median (IQR) 127.0 (93.0, 166.0) 162.0 (130.0, 184.5)
TC (mg/dl); mean ± SD 167.7 ± 42.0 198.5 ± 61.0
Triglycerides (mg/dl); median (IQR) 124.0 (105.0, 142.0) 115.0 (106.0, 124.0)
LDL-C <70 mg/dl† 24.3 (145/597) 11.4 (16/140)
Distance to LDL-C <70 mg/dl (mg/dl)‡ 19.0 (7.0, 31.0) 25.0 (19.0, 50.0)
*CHD patients: last recorded lipid profile prior to physician visit, ACS patients: within 24 h of 
admission for ACS event. †ECS/EAS guidelines for very high-risk patients.5 ‡For patients not at target. 
LDL-C - low-density lipoprotein cholesterol, 
HDL-C - high-density lipoprotein cholesterol, TC - total cholesterol
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used statin (63.8%), followed by simvastatin (27%), 
and rosuvastatin (8.7%). When statin potency was 
normalized to Atorvastatin, the mean daily dosage 
was calculated to be 31 ± 18 mg. Of the ACS patients, 
84.3% were on statin monotherapy, 12.9% were on a 
combination of a statin and ezetimibe, and 2.1% on a 
combination of a statin and other non-statin. Atorvastatin 
was the most commonly used statin (52.9%), followed 
by simvastatin (39.3%), and rosuvastatin (4.3%). 
The mean atorvastatin equivalent daily dosage was 
24 ± 13 mg. At the 4-month follow-up point, 60.4% 
of the ACS patients were on statin monotherapy, while 
38.8% were on a combination of statin and ezetimibe. 
The prescription patterns of the different statins differed 
from baseline, with a higher proportion of patients 
receiving Atorvastatin (52.9% versus 90.6%) and a 
Table 4 - Lipid-lowering therapy at baseline  in both cohort of ACS and CHD enrolled in hyperlipidemia in Saudi Arabia study.
Lipid-lowering therapy Stable CHD*
N=597
ACS
Hospital admission
n=140
4-month follow-up
n=139
Statin therapy (%) 99.8 (596/597) 92.7 (139/140) 100.0 (139/139)
Atorvastatin 63.8 (381/597) 52.9 (74/140) 90.6 (126/139)
Fluvastatin 0.2 (1/597) 0.0 (0/140) 0.0 (0/139)
Lovastatin 0.0 (0/597) 0.0 (0/140) 0.0 (0/139)
Pitavastatin 0.2 (1/597) 0.0 (0/140) 0.0 (0/139)
Pravastatin 0.0 (0/597) 0.7 (1/140) 0.0 (0/139)
Rosuvastatin 8.7 (52/597) 4.3 (6/140) 7.9 (11/139)
Simvastatin 27.0 (161/597) 39.3 (55/140) 1.4 (2/139)
Statin daily dose – atorvastatin eq. (mg/day)† 31 ± 18 (n = 597) 24 ± 13 (n = 140) 41 ± 15 (n = 139)
Statin monotherapy (%) 84.3 (503/597) 84.3 (118/140) 60.4 (84/139)
Non-statin monotherapy (%) 0.2 (1/597) 0.7 (1/140) 0.0 (0/139)
Statin + ezetimibe 14.6 (87/597) 12.9 (18/140) 38.8 (54/139)
Statin + other non-statin 1.0 (6/597) 2.1 (3/140) 0.7 (1/139)
*Lipid-lowering therapy (LLT) at time of latest lipid profile; †dose equivalents calculated.11 Data presented as mean ± standard deviation, or 
percentage (n/N). CHD - coronary heart disease, ACS - acute coronary syndrome
Table 3 - Multiple logistic regression model for an LDL level of <70 mg/dl at baseline in both cohort of ACS 
and CHD enrolled in hyperlipidemia in Saudi Arabia study.
Variable CHD patients ACS patients
OR (95% CI) P-value OR (95% CI) P-value
Age ≥70 years 1.17 (0.71-1.92) 0.53 8.16 (1.79-37.30)    0.0068
Female gender 1.07 (0.64-1.81) 0.79 0.30 (0.05-1.88) 0.20
BMI > 30 kg/m2 0.71 (0.46-1.08) 0.11 1.27 (0.31-5.22) 0.74
Current smoking 0.82 (0.42-1.57) 0.54 0.85 (0.20-3.50) 0.82
Sedentary lifestyle 0.35 (0.30-0.55)  <0.0001 0.27 (0.07-1.07)     0.0624
Stable angina 0.986 (0.55-1.76) 0.96 0.65 (0.11-3.94) 0.64
Type 2 diabetes 1.81 (1.14-2.89) 0.01 0.47 (0.13-1.73) 0.26
Hypertension 0.70 (0.44-1.13) 0.14 0.65 (0.18-2.34) 0.51
Statin dose 
(atorvastatin eq. 
mg/day)
1.01 (0.998-1.02) 0.11 1.01 (0.97-1.06) 0.60
BMI - body mass index, the model includes all displayed variables, which were selected based on clinical 
relevance. LDL-C - low-density lipoprotein cholesterol, CHD - coronary heart disease, ACS - acute coronary 
syndrome, BMI - body mass index
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lower proportion receiving simvastatin (39.3% versus 
1.4%). The mean Atorvastatin equivalent daily statin 
dosage had increased from 24 ± 13 mg at admission to 
41 ± 15 mg at 4 months. 
Events during follow-up for ACS patients. None of 
the ACS patients died during the 4-month follow-up 
period. There was no occurrence of MI or stroke, and 
no patients underwent PCI or CABG. Only 2 of the 
patients that were treated with LLT prior to admission 
required rehospitalization. There was no increased 
untoward effects reported with the increase of the statin 
dose over time.
Discussion. Dyslipidemia International Study 
II was established in order to specifically address 
hyperlipidemia in patients with either stable CHD or 
ACS, and to evaluate their treatment. Patients from 
Saudi Arabia, a country with alarming prevalence of 
cardiovascular risk factors, attainment of an LDL-C 
level of <70 mg/dl was poor. Furthermore, for the 
patients admitted to the hospital because of an ACS, 
LLT intensification was inadequate.
As in the rest of the world, hyperlipidemia is 
becoming more prevalent in Saudi Arabia as the average 
age and income of the population increase.12 In DYSIS, 
it was shown that only 26.4% of Saudi patients classed 
as being at very high cardiovascular risk had an LDL-C 
level of <70 mg/dl, despite being treated with statins.13 
A high level of under-treatment of these patients was 
indicated, a finding that was also reported for the 
Arabian Gulf cohort of CEPHEUS.7 
Comorbidities and cardiovascular risk factors were 
highly prevalent in both the patients with stable CHD 
and those admitted to the hospital for ACS. Obesity was 
extremely common, in particular for the ACS patients 
(79.3%). In comparison to the DYSIS II data for the 
Middle East and Africa region combined (Manuscript 
in preparation), almost 30% of the ACS patients from 
Saudi Arabia were classed as obese. This is in agreement 
with data presented by Yatsuya et al14 where Saudi 
Arabia was shown to have one of the highest levels 
of overweight and obesity in the East Mediterranean 
region. A sedentary lifestyle was also common (69.4% 
and 75% of LLT-treated CHD and ACS patients, 
respectively), as was smoking (16.8% and 41.4%, 
respectively), suggesting that better patient education 
would be beneficial for improving these modifiable risk 
factors.15 Similar to previous studies in patients at high 
cardiovascular risk, hypertension and diabetes mellitus 
were noted for large proportions of patients.4,7,8
For the CHD patients, less than a quarter (24.3%) 
attained LDL-C <70 mg/dl, despite the finding of a 
relatively low mean LDL-C value in comparison to the 
average values quoted in other studies.4,7 Poor LDL-C 
target attainment was also reported for the very high 
risk LLT-treated patients in the Middle East cohort 
of DYSIS and the Arabian Gulf countries included in 
CEPHEUS, with 30.5% and 31.9% of these patients, 
respectively, achieving a level of <70 mg/dl.6,7 We found 
that the distance to target for those not at goal was quite 
small, indicating that even small reductions in LDL-C 
levels would greatly increase target attainment. This is 
corroborated by the high proportion of CHD patients 
(68%) achieving a level of <100 mg/dl in a previous 
study in Saudi Arabia.9 After multivariable analysis, the 
only factors that were found to be associated with an 
LDL-C level below 70 mg/dl were a sedentary lifestyle, 
which decreased the likelihood, and type 2 diabetes, 
which increased the likelihood. In CEPHEUS, Arafah et 
al7 also identified a history of diabetes as being predictive 
of target achievement. A potential explanation for this 
finding is that patients with diabetes may be more aware 
of the seriousness of their health situation and so might be 
more adherent to pharmacological therapy and lifestyle 
improvements. Furthermore, they would be likely to 
have greater contact with physicians (cardiologists and 
endocrinologists). Al Shammeri et al9 found that a high 
proportion of the stable CHD patients included in their 
study did not have a recent LDL-C level documented in 
their medical notes. It therefore appears that increased 
attention to lipid testing may have a positive effect on 
target attainment in CHD patients.
Low-density lipoprotein cholesteroltarget attainment 
according to pre-ACS risk level was extremely poor for 
the ACS patients, reaching just over 11% for those at 
very high risk. In contrast to the patients with stable 
CHD, the only factor included in the multivariable 
analysis that was found to be associated with ACS 
patients displaying an LDL-C level of <70 mg/dl at 
admission was an age of 70 years or above.
The low levels of target achievement suggest highly 
ineffective use of LLT in these very high risk patients. 
While all subjects were being treated with LLT, the 
mean atorvastatin equivalent daily dose was only 31 mg 
for the stable CHD patients and 24 mg for the ACS 
patients at admission. While the dosage by the 4-month 
follow-up point had increased to 41 mg for the ACS 
patients, this is still only a medium intensity. Nicholls 
et al16 reported significant coronary plaque regression 
when intensive Atorvastatin (80 mg/day) or rosuvastatin 
(40 mg/day) therapy was prescribed to patients with 
CHD.16 Furthermore, in the Pravastatin or Atorvastatin 
Evaluation and Intensive Therapy-Thrombolysis in 
Myocardial Infarction-22 (PROVE IT–TIMI 22), 
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patients with an ACS who were treated with intensive 
statin therapy were found to have a lower likelihood of 
death or a major cardiovascular event in comparison to 
the patients that received standard therapy.17 Similar 
advantages of intensive LLT were found in the GWTG 
database and the Translational Research Investigating 
Underlying Disparities in Acute Myocardial Infarction 
Patients’ Health Status (TRIUMPH) study.18 A number 
of other trials have also demonstrated advantages in 
terms of lipid-lowering and occurrence of cardiovascular 
adverse events when more intensive statin treatment is 
prescribed.19 The majority of these studies utilized an 
Atorvastatin dose of 80 mg as the intensive arm, which 
highlights the low average doses used for the patients in 
the present analysis. In the Middle Eastern CEPHEUS 
patients, although exact normalized statin doses were 
not reported, the majority of patients were being treated 
with the equivalent of ≤30 mg of atorvastatin per day.7 In 
DYSIS, which was carried out in 2011-2012, the most 
commonly prescribed statin dose for the very high risk 
patients in the Middle East countries was equivalent to 
20 mg per day.6 The increase in statin dose from DYSIS 
to DYSIS II may indicate improvement in the way in 
which these drugs are used for managing LDL-C levels 
in CHD patients in Saudi Arabia; however, there is 
clearly room for treatment intensification, in particular 
for patients who have experienced an ACS.
The addition of a non-statin agent to statin 
monotherapy is an alternative method to intensify LLT 
for very high risk patients. In the Improved Reduction 
of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT), it was shown that, in patients that 
had suffered an ACS, LDL-C levels were reduced to a 
greater extent with the use of ezetimibe in combination 
with simvastatin (93.8 mg/dl to 53.7 mg/dl during the 
trial) than with simvastatin alone (93.8 mg/dl to 69.5 
mg/dl during the study).20 The study also demonstrated 
a 2% lower rate of the primary endpoint (cardiovascular 
death, non-fatal MI, UA requiring hospitalization, 
coronary revascularization, or non-fatal stroke) 
achievement for the patients receiving combination 
therapy. In addition, increased plaque regression has 
been demonstrated for combination therapy (ezetimibe 
plus rosuvastatin) in comparison to statin monotherapy 
(rosuvastatin alone) in patients with CHD.21,22 In the 
present study, ezetimibe use was relatively uncommon 
at baseline (14.5% and 12.9% for CHD and ACS 
patients, respectively); however, by the 4-month 
follow-up point, 38.8% of the ACS patients were being 
treated with this agent. Interestingly, this is much higher 
than the proportions of patients in other Middle Eastern 
countries that participated in DYSIS II (Manuscripts in 
preparation). Such evidence of treatment intensification 
is promising, but there remains a discrepancy between 
optimal therapy and that used in the real-world.
One limitation to this analysis is the low number of 
ACS patients with a full lipid profile collected during 
the acute phase and the follow-up period. This prevents 
us from also establishing a true picture of the effects 
of changes that were made to the LLT after admission. 
Furthermore, no adverse cardiovascular events were 
recorded for the ACS patients during the relatively short 
follow-up period, and such events were not monitored 
in the patients with stable CHD. This prevents us from 
evaluating the associations between lipid levels, LLT, 
and long-term cardiovascular outcome.
In conclusions, despite the known benefits of 
achieving a low level of LDL-C, few patients had 
reached the recommended target for individuals with 
CHD. While all patients were being treated with LLT 
prior to enrolment in the study, the mean daily dosage 
was low. Treatment was intensified for the patients who 
were admitted to hospital owing to an ACS; however, 
the statin dosages remained low. The data indicate that 
there is a huge scope for improving the treatment of 
hyperlipidemia in high-risk patients in Saudi Arabia.
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